120 related articles for article (PubMed ID: 38807029)
1. Synthesis and in vitro cytotoxicity of benzoxazole-based PPARα/γ antagonists in colorectal cancer cell lines.
Moreno-Rodríguez N; Laghezza A; Cerchia C; Sokolova DV; Spirina TS; De Filippis B; Romanelli V; Recio R; Fernández I; Loiodice F; Pokrovsky VS; Ammazzalorso A; Lavecchia A
Arch Pharm (Weinheim); 2024 May; ():e2400086. PubMed ID: 38807029
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic effect of a family of peroxisome proliferator-activated receptor antagonists in colorectal and pancreatic cancer cell lines.
Ammazzalorso A; De Lellis L; Florio R; Bruno I; De Filippis B; Fantacuzzi M; Giampietro L; Maccallini C; Perconti S; Verginelli F; Cama A; Amoroso R
Chem Biol Drug Des; 2017 Nov; 90(5):1029-1035. PubMed ID: 28544586
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of benzoxazole containing indole analogs as peroxisome proliferator-activated receptor-γ/δ dual agonists.
Gim HJ; Cheon YJ; Ryu JH; Jeon R
Bioorg Med Chem Lett; 2011 May; 21(10):3057-61. PubMed ID: 21482466
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
5. Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.
Kalajdzic T; Faour WH; He QW; Fahmi H; Martel-Pelletier J; Pelletier JP; Di Battista JA
Arthritis Rheum; 2002 Feb; 46(2):494-506. PubMed ID: 11840453
[TBL] [Abstract][Full Text] [Related]
6. Regulation of peroxisome proliferator-activated receptors (PPAR) α and -γ of rat brain astrocytes in the course of activation by toll-like receptor agonists.
Chistyakov DV; Aleshin SE; Astakhova AA; Sergeeva MG; Reiser G
J Neurochem; 2015 Jul; 134(1):113-24. PubMed ID: 25818681
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications.
Mandal S; Faizan S; Raghavendra NM; Kumar BRP
Mol Divers; 2023 Dec; 27(6):2605-2631. PubMed ID: 36437421
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide peroxisome proliferator-activated receptors α antagonists.
Ammazzalorso A; Carrieri A; Verginelli F; Bruno I; Carbonara G; D'Angelo A; De Filippis B; Fantacuzzi M; Florio R; Fracchiolla G; Giampietro L; Giancristofaro A; Maccallini C; Cama A; Amoroso R
Eur J Med Chem; 2016 May; 114():191-200. PubMed ID: 26974385
[TBL] [Abstract][Full Text] [Related]
9. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of a panel of per- and polyfluoroalkyl substances (PFAS), fatty acids, and pharmaceuticals in peroxisome proliferator-activated receptor (PPAR) alpha, PPAR gamma, and estrogen receptor assays.
Evans N; Conley JM; Cardon M; Hartig P; Medlock-Kakaley E; Gray LE
Toxicol Appl Pharmacol; 2022 Aug; 449():116136. PubMed ID: 35752307
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of novel benzothiazole amides: Evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines.
Ammazzalorso A; De Lellis L; Florio R; Laghezza A; De Filippis B; Fantacuzzi M; Giampietro L; Maccallini C; Tortorella P; Veschi S; Loiodice F; Cama A; Amoroso R
Bioorg Med Chem Lett; 2019 Aug; 29(16):2302-2306. PubMed ID: 31272790
[TBL] [Abstract][Full Text] [Related]
13. Activation of peroxisome proliferator-activated receptor gamma does not explain the antiproliferative activity of the nonsteroidal anti-inflammatory drug indomethacin on human colorectal cancer cells.
Hawcroft G; Gardner SH; Hull MA
J Pharmacol Exp Ther; 2003 May; 305(2):632-7. PubMed ID: 12606626
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptors-α and -γ, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue.
Rosell M; Hondares E; Iwamoto S; Gonzalez FJ; Wabitsch M; Staels B; Olmos Y; Monsalve M; Giralt M; Iglesias R; Villarroya F
Endocrinology; 2012 Mar; 153(3):1162-73. PubMed ID: 22253419
[TBL] [Abstract][Full Text] [Related]
15.
Feng XY; Ding TT; Liu YY; Xu WR; Cheng XC
J Biomol Struct Dyn; 2021 Mar; 39(5):1853-1864. PubMed ID: 32189570
[TBL] [Abstract][Full Text] [Related]
16. Oxidized low density lipoprotein activates peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARgamma through MAPK-dependent COX-2 expression in macrophages.
Taketa K; Matsumura T; Yano M; Ishii N; Senokuchi T; Motoshima H; Murata Y; Kim-Mitsuyama S; Kawada T; Itabe H; Takeya M; Nishikawa T; Tsuruzoe K; Araki E
J Biol Chem; 2008 Apr; 283(15):9852-62. PubMed ID: 18208815
[TBL] [Abstract][Full Text] [Related]
17. Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis.
D'Argenio G; Petillo O; Margarucci S; Torpedine A; Calarco A; Koverech A; Boccia A; Paolella G; Peluso G
J Biol Chem; 2010 Aug; 285(35):27078-27087. PubMed ID: 20558736
[TBL] [Abstract][Full Text] [Related]
18. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
19. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
[TBL] [Abstract][Full Text] [Related]
20. A dominant negative human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms.
Semple RK; Meirhaeghe A; Vidal-Puig AJ; Schwabe JW; Wiggins D; Gibbons GF; Gurnell M; Chatterjee VK; O'Rahilly S
Endocrinology; 2005 Apr; 146(4):1871-82. PubMed ID: 15661858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
